0 Items
Select Page

Giardia

Giardia lamblia is an anaerobic, flagellated eukaryotic protozoan and member of the Hexamitidae family of protozoa. Giardia lamblia infects and colonises the small intestine of humans and mammals, causing a globally-common diarrheal disease, known as giardiasis.

The Native Antigen Company offers Giardia monoclonal antibodies for use in immunoassay development.

Giardia Background

Giardia lamblia exists in two forms, as a dormant cyst that infects the small intestine and as a trophozoite – a vegetative form that excysts from the cyst. Trophozoites replicate within the intestine causing the symptoms associated with giardiasis. Both cysts and trophozoites are present in contaminated faeces, but trophozoites do not survive for long periods in the environment. G. lamblia cysts are found in soil and water, and on surfaces contaminated by faeces from an infected individual. Giardiasis infection in humans occurs by transmission of dormant G. lamblia cysts via the faecal oral route or through ingestion of contaminated food and water (CDC).

Giardia Antibodies

Our Giardia-specific antibodies are specific to the trophozoite protein of Giardia lamblia. Our Giardia antibodies do not cross react with Campylobacter spp., Clostridium difficile, Cryptosporidium parvum, Entamoeba histolytica, Escherichia coli, Helicobacter pylori, Listeria monocytogenes, Salmonella spp., Shigella spp. or Staphylococcus aureus.

We also have two monoclonal antibodies available, which may be used as pairs in immunoassay development.

Questions?

Check out our FAQ section for answers to the most frequently asked questions about our website and company.

Using Adenoviruses to Fight Cancer

In the second of a 2-part series, we discuss how adenoviruses are being developed to treat cancer and some of the hurdles these platforms face from our own immune systems. Curing cancer is one of the biggest challenges of the 21st century. Our knowledge of cancer’s...

New Immunofluorescence Data for our CMV, Yellow Fever and Ebola Antibodies

In September 2018 The Native Antigen Company and Virology Research Services (VRS) were awarded the Medical Research Council (Proximity to Discovery Award for Knowledge Exchange) to test a large panel of our viral antibodies in immunofluorescence applications. This...

Why are ticks such good vectors of pathogens?

In this blog, Professor Patricia Nuttall discusses what makes ticks such effective vectors of pathogens and how we might prevent the spread of tick-borne diseases. About Patrica Nuttall Pat Nuttall is Emeritus Professor of Arbovirology in the Department of Zoology,...

Dengue in 2019

What's going on with dengue? Dengue virus (DENV) has been in the news a lot recently. The number of reported cases continues to climb year-on-year and 2019 has been especially bad. Rio de Janeiro has seen a 45% increase in dengue cases in the first two months of 2019...

Zika Prevalence in Suriname – an insight into assay cross-reactivity

A recent study published by Langerak et al tested for the seroprevalence of Zika virus in Suriname populations and evaluated the comparative effectiveness of using a commercial ELISA and a standard Virus Neutralisation Assay. Here we discuss the study, its results,...

Get in Touch

We sometimes send exclusive information and offers to our customers - please let us know if you are happy to receive these

5 + 9 =

Live Customer Feedback